NHS England Secures Long-Term Access to Cystic Fibrosis Drugs
Deal with Vertex Pharmaceuticals ensures availability of life-changing treatments for thousands of patients.
- Agreement follows extensive negotiations and patient advocacy efforts.
- Drugs Kaftrio, Symkevi, and Orkambi to be available for all eligible patients.
- New NICE appraisal method allows higher spending on severe disease treatments.
- Over 11,000 people in the UK affected by cystic fibrosis stand to benefit.
- Similar agreements expected soon in Scotland, Wales, and Northern Ireland.
Boston Globe 
Stat News 
BBC 
The Telegraph 
Evening Standard 
